NeuroDome Secures Tens of Millions in Series A Funding to Advance Non-Invasive Deep Brain Neuromodulation Platform

Feb 25, 2025 20:09 CST Updated 20:09

Neurodome

Neurodome, Inc.

Instrument Family

Medical Device Media Reporting Pioneer

Share Professional Medical Device Knowledge

Source: NeuroDome

Recently, Neurodome, Inc. (hereinafter referred to as "Neurodome"), an innovator focusing on non-invasive deep brain neuromodulation technology, has successfully completed a multi-million yuan Series A round of financing. This round of financing was led byHuafang Capital and iFlytek VenturesCo-led by,Heying CapitalFollow-up investment, Xingyuan Zhiting serves as the exclusive financial advisor for this round of financing.

This round of financing will help the company accelerate the continuous exploration and development of Temporal Interference (TI) technology in the field of brain science, promote multi-scenario product solutions, and advance clinical registration, product certification, and commercialization for various indications.

Medical research collaboration advances efficiently, with interim results far exceeding expectations.

Neurodome always regards clinical needs as the guiding principle, efficiently advancing clinical exploration and industrial implementation based on TI technology. Among its achievements, the TI Research Edition product, only one year after its release, has established collaborations with nearly a hundred top clinical centers and university research institutions both in China and internationally. It has cumulatively conducted over a thousand TI research clinical cases across dozens of indications, including depression, Parkinson's disease, essential tremor, and sleep disorders.Post-Traumatic Stress Disorder, epilepsy, etc., have all achieved exciting phased clinical results, leading the progress globally, providing a new option for non-invasive deep brain neuromodulation in neuroscience and psychiatric disorders.

Focusing on Brain Science Challenges, TI's Technical Advantages Stand Out

The field of brain science has a huge potential for therapeutic demand. The number of patients with various brain diseases in China is close to 130 million, including more than 50 million patients with depression. The burden caused by brain diseases accounts for 23% of the total disease burden. Current treatment methods have many shortcomings, making it difficult to balance safety and efficacy. Invasive treatments carry high risks, while non-invasive interventions struggle to achieve both depth and precision. This challenging yet fascinating blue ocean track urgently calls for new technological leaders who can meet the clinical needs of being non-invasive, deep-brain, precise, and multi-targeted.

Neurodome, Inc. has been deeply engaged in the field of non-invasive neuromodulation for nearly a decade, continuously refining TI technology and taking the lead in mastering and achieving precise non-invasive deep-brain neuromodulation using TI in humans. Neurodome’s TI products can accurately output various stimulation signal patterns, finely adjust parameters according to clinical needs, ensuring the accuracy, effectiveness, and repeatability of treatment protocols. These products perfectly enable non-invasive, deep-brain, high-precision, multi-target central nervous system stimulation and intervention, with wide applications in the treatment of various neurological and psychiatric disorders.

Continuous Iteration of Multi-Scenario TI Product Solutions, TI Experience Exported Globally

Neurodome, Inc. has established a comprehensive product matrix, achieving full coverage of scenarios from research to clinical settings and from in-hospital to out-of-hospital environments. Its research products have already been commercially marketed. Recently, Neurodome, Inc. launched new product solutions, TI – TMS and TI-TUS, which integrate innovative technologies, providing new tools and technical solutions for clinical research and applications.

In September 2024, the first Global TI Summit, International Meeting on Temporal Interference Brain Stimulation, grandly opened in London. As an industry-leading enterprise, Neurodome showcased its significant breakthroughs in TI technology development, clinical applications, and product innovation to global clinicians and researchers in the TI field. Together with top neuroscientists, medical experts, and industry leaders worldwide, Neurodome discussed the future development of TI technology in the field of neuromodulation.

With courage and perseverance, we remain committed to our mission. In the future, Neurodome will continue to drive innovation, focusing on the continuous iteration of TI technology. Centered on deep brain modulation, we will develop a multi-physical factor modulation product line covering the functional cortex and central-peripheral nervous systems, creating a globally leading non-invasive deep brain neuromodulation platform based on TI stimulation.

Research Scenario Product (Left) and Clinical Scenario Product (Right)

New Generation TI-TMS Product Prototype

New Generation TI-TUS Prototype

Regarding this round of financing,Dr. Wangqian Luo, Partner of Huafang CapitalThe brain is the most complex and sophisticated organ in the human body, and research on the human brain has always been one of the ultimate challenges in life sciences. However, non-invasive research methods for the brain are still very limited, let alone functional modulation. Therefore, Huafang Capital has been continuously paying attention to the progress and application of cutting-edge technologies in brain science. Through the revolutionary TI technology, Neurodome has achieved precise deep-brain multi-target modulation in a non-invasive way, effectively breaking through the bottlenecks of existing technologies. This not only provides a powerful tool for brain science research but also brings an epoch-making innovative therapy to meet huge unmet clinical needs. Currently, Neurodome has completed the assembly of a world-class talent team and accumulated leading technology. It continues to lead the industry in clinical progress and technological iteration, demonstrating the outstanding efficacy and safety of its products in dozens of indications and hundreds of human trials. We are highly looking forward to joining hands with Neurodome to create new miracles in the field of human brain analysis and modulation, which holds infinite possibilities.

Dr. Ding Jingna, Vice President of iFlytek Ventures and Head of Healthcare & Life SciencesRepresentation: iFlytek Group has always paid high attention to the integration of brain science and artificial intelligence, as well as the opportunities for scientific and technological innovation and project implementation in this field. Neurodome possesses original底层 technologies and has a deep collaboration with Nir Grossman's team, which was the first in the world to propose TI non-invasive deep brain neural stimulation technology. Their technology has been recognized by international experts. We are confident that Neurodome, based on this底层 technology, is expected to provide more effective and convenient treatment and intervention methods for complex nervous system diseases such as depression, Parkinson's disease, Alzheimer's disease, and sleep disorders through non-invasive means. We also look forward to Neurodome having a deeper integration with artificial intelligence technology in the future, achieving personalized and precise treatment models, and becoming a leading innovative technology enterprise in safeguarding human brain health.

Feng Zhihua, President of Heying CapitalStated: Brain science is a key focus area for Heying Capital. To this end, we have established the first domestic brain-computer interface special fund in China, dedicated to discovering potential companies with revolutionary technologies. Neurodome's TI non-invasive deep brain precise neuromodulation technology is leading globally in clinical progress and product development, with significant market potential in areas such as mental illness and neurodegenerative diseases. We are highly optimistic about the application prospects of TI technology in the field of brain science and look forward to Neurodome's innovative products benefiting patients with brain disorders as soon as possible. We also anticipate that Neurodome will strengthen its collaboration with Heying Capital’s brain science ecosystem for mutual benefit and to promote innovation and development in China's brain science sector.

Shen Yuxiao, Managing Director of XY CapitalNeurodome, as a global leader in the field of TI non-invasive deep brain neuromodulation, has reached the next significant milestone for this disruptive non-invasive modulation technology through solid technical accumulation and highly efficient clinical progress. We are honored to serve as the exclusive financial advisor to Neurodome, assisting the company in completing its Series A financing round. We look forward to Neurodome’s continued leadership and innovation in TI, contributing Chinese experience and innovative TI solutions to the global neuroscience community.

END

China's First: Acquisition of Japan's "Machine King" Top Business

Just now, the FDA urgently revoked the layoff notice

$1.6 Billion: Boston Scientific Makes a Big Move

"M&A Maniac" Acquires Neurodome, Inc.

Buffett Sells $1 Billion, Giant Plummets 17%

"Female Steve Jobs" Plans Next Venture from Prison

Top 10 ESG Companies in the Chinese Medical Device Industry Listed on the Hong Kong Stock Exchange

Mindray Participates in Building the Country's First Ultrasound Factory

Weigao, IPO to be Reviewed

Siemens Healthineers, 11 Billion Shares Sold

BusinessBusiness cooperation email: qxzj@landianyiliao.com